File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Human CD34+ cell preparations contain over 100-fold greater NOD/SCID mouse engrafting capacity than do CD34- cell preparations

TitleHuman CD34<sup>+</sup> cell preparations contain over 100-fold greater NOD/SCID mouse engrafting capacity than do CD34<sup>-</sup> cell preparations
Authors
Issue Date2001
Citation
Experimental Hematology, 2001, v. 29, n. 7, p. 910-921 How to Cite?
AbstractObjective. The CD34 cell surface marker is used widely for stem/progenitor cell isolation. Since several recent studies reported that CD34- cells also have in vivo engrafting capacity, we quantitatively compared the engraftment potential of CD34+ vs CD34- cell preparations from normal human placental/umbilical cord blood (CB), bone marrow (BM), and mobilized peripheral blood (PBSC) specimens, using the nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model. Methods. CD34+ and CD34- cell preparations were purified by four different approaches in 14 individual experiments involving 293 transplanted NOD/SCID mice. In most experiments, CD34+ cells were depleted twice (CD34=) in order to obtain efficient depletion of CD34+ cells from the CD34- cell preparations. Results. Dose-dependent levels of human hematopoietic cells were observed after transplantation of CD34+ cell preparations. To rigorously assess the complementary CD34- cell preparations, cell doses 10- to 1000-fold higher than the minimum dose of the CD34+ cell preparations necessary for engraftment were transplanted. Nevertheless, of 125 NOD/SCID mice transplanted with CD34- cell preparations purified from the same starting cells, only six mice had detectable human hematopoiesis, by flow cytometric or PCR assay. Conclusions. CD34- cells provide only a minor contribution to hematopoietic engraftment in this in vivo model system, as compared to CD34+ cells from the same samples of noncultured human cells. Hematopoiesis derived from actual CD34- cells is difficult to distinguish from that due to CD34+ cells potentially contaminating the preparations. Copyright © 2001 International Society for Experimental Hematology.
Persistent Identifierhttp://hdl.handle.net/10722/294486
ISSN
2019 Impact Factor: 2.82
2015 SCImago Journal Rankings: 1.341
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorGao, Zhigang-
dc.contributor.authorFackler, Mary Jo-
dc.contributor.authorLeung, Wing-
dc.contributor.authorLumkul, Rachata-
dc.contributor.authorRamirez, Manuel-
dc.contributor.authorTheobald, Narda-
dc.contributor.authorMalech, Harry L.-
dc.contributor.authorCivin, Curt I.-
dc.date.accessioned2020-12-03T08:22:51Z-
dc.date.available2020-12-03T08:22:51Z-
dc.date.issued2001-
dc.identifier.citationExperimental Hematology, 2001, v. 29, n. 7, p. 910-921-
dc.identifier.issn0301-472X-
dc.identifier.urihttp://hdl.handle.net/10722/294486-
dc.description.abstractObjective. The CD34 cell surface marker is used widely for stem/progenitor cell isolation. Since several recent studies reported that CD34- cells also have in vivo engrafting capacity, we quantitatively compared the engraftment potential of CD34+ vs CD34- cell preparations from normal human placental/umbilical cord blood (CB), bone marrow (BM), and mobilized peripheral blood (PBSC) specimens, using the nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model. Methods. CD34+ and CD34- cell preparations were purified by four different approaches in 14 individual experiments involving 293 transplanted NOD/SCID mice. In most experiments, CD34+ cells were depleted twice (CD34=) in order to obtain efficient depletion of CD34+ cells from the CD34- cell preparations. Results. Dose-dependent levels of human hematopoietic cells were observed after transplantation of CD34+ cell preparations. To rigorously assess the complementary CD34- cell preparations, cell doses 10- to 1000-fold higher than the minimum dose of the CD34+ cell preparations necessary for engraftment were transplanted. Nevertheless, of 125 NOD/SCID mice transplanted with CD34- cell preparations purified from the same starting cells, only six mice had detectable human hematopoiesis, by flow cytometric or PCR assay. Conclusions. CD34- cells provide only a minor contribution to hematopoietic engraftment in this in vivo model system, as compared to CD34+ cells from the same samples of noncultured human cells. Hematopoiesis derived from actual CD34- cells is difficult to distinguish from that due to CD34+ cells potentially contaminating the preparations. Copyright © 2001 International Society for Experimental Hematology.-
dc.languageeng-
dc.relation.ispartofExperimental Hematology-
dc.titleHuman CD34<sup>+</sup> cell preparations contain over 100-fold greater NOD/SCID mouse engrafting capacity than do CD34<sup>-</sup> cell preparations-
dc.typeConference_Paper-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0301-472X(01)00654-3-
dc.identifier.pmid11438214-
dc.identifier.scopuseid_2-s2.0-0034955676-
dc.identifier.volume29-
dc.identifier.issue7-
dc.identifier.spage910-
dc.identifier.epage921-
dc.identifier.isiWOS:000170057400013-
dc.identifier.issnl0301-472X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats